Table 2.
Active trials of T-cell-engaging bispecific antibodies in RRMM.
| Trial ID [References] | Treatment | Phase | Enrollment | Trial Title |
|---|---|---|---|---|
| NCT02514239 [67] | AMG 420 (BI 836909) | I | 43 | An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Doses of BI 836909 in Relapsed and/or Refractory Multiple Myeloma Patients |
| NCT03287908 [68] | AMG 701 | I/II | 270 | A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects with Multiple Myeloma (ParadigMM-1B) |
| NCT03761108 [69] | REGN5458 | I/II | 74 | Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma |
| NCT04083534 | REGN5459 | I/II | 56 | Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma |
| NCT03145181 [70] | Teclistamab (JNJ-64007957) | I | 160 | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody® Antibody in Subjects with Relapsed or Refractory Multiple Myeloma |
| NCT04108195 | Daratumumab + Talquetamab + Teclistamab (JNJ-64007957) | I | 100 | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma |
| NCT03269136 [71,72,73] | PF-06863135 | I | 80 | A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of Pf-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, In Patients with Relapsed/Refractory Advanced Multiple Myeloma (MM) |
| NCT03486067 [74] | CC-93269 | I | 120 | A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects with Relapsed and Refractory Multiple Myeloma. |
| NCT03933735 [75,76] | TNB-383B | I | 72 | A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma |
| NCT04184050 [77] | HPN217 | I/II | 70 | A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma |